一只涨450%，一只涨150%，这两家“凤凰之星”获奖公司做对了什么？

Core Viewpoint - The significant stock price increases of Kangfang Biopharma and Pop Mart, which rose over 150% and 450% respectively, reflect the accurate predictions of the "Phoenix Star Listed Company Awards" regarding high-quality investment targets [1][4][18]. Group 1: Performance and Growth - Kangfang Biopharma achieved a revenue of 1.412 billion yuan in the first half of 2025, marking a year-on-year growth of 33.7%, driven by the commercialization of core products [5]. - Pop Mart reported a revenue of 13.88 billion yuan during the same period, with a remarkable year-on-year growth of 204.4%, showcasing the strong monetization capability of cultural IP operations [8]. - Both companies' growth is attributed to stable revenue contributions from their core businesses, with Kangfang Biopharma focusing on dual-antibody drug matrices and Pop Mart leveraging its leading IP series [8]. Group 2: Globalization Strategy - Kangfang Biopharma is actively pursuing a global strategy, with key products like Cardunili and Yivosi being central to its international expansion. The company has authorized Summit to commercialize Yivosi globally under a deal worth up to $5 billion [9]. - Pop Mart adopts a localized international strategy, signing artists globally to cater to diverse consumer needs and launching region-specific products, such as Thai-themed LABUBU products and collaborations with famous artworks in Paris [9]. Group 3: Industry Trends - The innovative pharmaceutical sector, where Kangfang Biopharma operates, is experiencing structural changes, with improved healthcare systems and accelerated drug approvals driving the growth of Chinese innovative drugs [12]. - Pop Mart is capitalizing on the rise of the IP economy, fueled by the increasing demand for emotional value consumption among Generation Z and the global popularity of "Guzi" culture [12]. Group 4: Evaluation Criteria - The "Phoenix Star Listed Company Awards" emphasizes long-term growth potential over short-term financial metrics, utilizing data analysis, expert reviews, and public voting to identify companies with sustainable value [13][14]. - The awards recognize Kangfang Biopharma's comprehensive layout from R&D to industrialization and Pop Mart's innovative capabilities in IP operations and global expansion potential [14].